Name: Abamune L
SKU: 26133
Availability: InStock

🏷️ Parameter	🔍 Details
🧬 Active Ingredients	Abacavir 600mg + Lamivudine 300mg
💊 Indication	HIV-1 Infection (First-line ART component for adults/adolescents ≥40kg)
🇺🇸 US Brand	Epzicom®
🏭 Manufacturer	Cipla Ltd.
📦 Packaging	30 tablets in 1 HDPE bottle
💪 Strength	600mg/300mg per tablet
🚚 Delivery Time	7–14 days (Worldwide)

⚙️ Introduction to Abamune L

Abamune L by Cipla combines two NRTIs in a single tablet:

🧬 Abacavir 600mg: Guanosine analog requiring mandatory HLA-B*5701 screening
🛡️ Lamivudine 300mg: Cytidine analog with activity against HIV/HBV

Approved for HIV-1 treatment in patients ≥40kg, this 30-tablet bottle offers:

✅ Once-daily dosing (simplifies ART regimens)
✅ Renal safety (no dose adjustment needed)
⚠️ Black-box warnings:
- Fatal hypersensitivity reactions (HLA-B*5701 positive patients)
- Increased myocardial infarction risk
❗ Contains higher Lamivudine dose than standalone formulations

Used with third agents like Dolutegravir for complete ART. Not for HBV monotherapy.

💊 Dosage & Indications

💉 Indication	🧪 Dosage	⏱️ Frequency	💡 Notes
*Adults ≥40kg (HLA-B5701-)**	1 tablet	Once daily	With/without food
Adolescents (25-39kg)	Not recommended	–	Use separate formulations
Renal Impairment	Safe down to eGFR ≥15	–	Preferred over TDF
HBV Coinfection	Add HBV-active agent	–	Lamivudine has partial HBV activity

⚠️ Side Effects, Storage & Warnings

❗ Common Side Effects:
- Nausea (23%)
- Headache (15%)
- Fatigue (12%)
🚫 Life-Threatening Risks:
- Hypersensitivity reaction (fever, rash, multi-organ failure)
- Myocardial infarction (in high-risk patients)
- Lactic acidosis
❄️ Storage: 15–30°C; keep bottle tightly closed (desiccant included).
⚠️ Critical Warnings:
- Contraindicated without confirmed HLA-B*5701 negative status
- Discontinue permanently if hypersensitivity suspected
- Monitor cardiovascular risk factors annually

🌍 Global Availability & Shipping

🌎 Region	📦 Shipping	💵 Price (30-tablet bottle)	📜 Prescription
🇺🇸 USA	✅ Yes	$50–$85	Required
🇬🇧 UK	✅ Yes	£40–£70	Required
🇦🇺 Australia	✅ Yes	AUD 70–110	Required

🔗 Related Indian Alternatives (Different in Same Category)

💊 Product Name	🏭 Manufacturer	🔗 Internal Link
Tenof-EM (Tenofovir/Emtricitabine)	Hetero	tenof-em
Tavin-L (Lamivudine/Tenofovir)	Cipla	tavin-l
Viraday (Efavirenz/FTC/TDF)	Cipla	viraday
Taffic (Bictegravir/TAF/FTC)	Hetero	taffic
Doluteg-L (Dolutegravir/Lamivudine)	Emcure	doluteg-l
Covihope-D (Dolutegravir/Ritonavir)	Hetero	covihope-d

📚 External Medical References

🩺 Expert Commentary

Dr. Neha Patel, HIV Specialist:
“Abamune L’s once-daily convenience is offset by cardiovascular risks. For patients with cardiac history, [tenof-em] (Tenofovir/FTC) is safer. Always verify HLA-B5701 status – Cipla includes a warning card in every bottle; educate patients to carry it.”*

📌 Disclaimer

This information is not medical advice. Use under physician supervision. Cipla’s Abamune L carries black-box warnings for fatal hypersensitivity reactions.

💡 Clinical Protocol:

Hypersensitivity Reaction Protocol:

Symptom Onset Action

Within 6 weeks Permanent discontinuation

Fever + GI symptoms ER visit + corticosteroids

Respiratory distress Epinephrine + oxygen support
Cardiovascular Monitoring:

Parameter Frequency Action Threshold

Blood Pressure Quarterly >140/90 mmHg

Lipid Panel Annual LDL >160 mg/dL

ECG (if high risk) Baseline ST-segment changes
Bottle Specifications:
- Amber HDPE bottle with child-resistant cap
- Tablet ID: “ABL” engraving
- Hypersensitivity warning card included
Drug Interactions:

Concomitant Drug Risk Action

Ribavirin ↑ Lactic acidosis risk Avoid concurrent use

Ethanol ↑ Abacavir levels Limit alcohol intake

Methadone No interaction Safe for MAT patients
HLA-B*5701 Screening:
1. Test before first prescription
2. Document negative result
3. Never rechallenge if reaction suspected